ArticleLipids in health and disease2025
Emerging risks of lipid-lowering therapy and low LDL levels: implications for eye, brain, and new-onset diabetes.
Article in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Reconceptualizing Dyslipidemia: Diversity of Lipid Imbalances and Their Clinical Implications; A Narrative Review.Health science reports · 2026Article
- Predicting Intraocular Pressure From Glaucoma Patients Receiving Medication Treatment Using Explainable Machine Learning.BioMed research international · 2026Article
- Atherosclerotic plaque, cardiovascular risk, and lipid-lowering strategies: a narrative review.Frontiers in cardiovascular medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerotic cardiovascular disease remains a major global health burden. Current guidelines emphasize aggressive lipid-lowering strategies, particularly those that reduce low-density lipoprotein cholesterol (LDL-C) levels. While effective in lowering cardiovascular risk, excessively low LDL-C may have unintended health consequences. LDL-C plays a critical physiological role in cellular structure and hormone synthesis. Emerging evidence links low LDL-C and high HDL-C with increased glaucoma risk. Statins, which are commonly used to lower LDL-C, may further increase this risk, raising concerns for patients with coronary artery disease. Low LDL-C has also been associated with gestational diabetes and intracranial hemorrhage, while statin therapy may contribute to new-onset diabetes mellitus. These findings highlight the need to reassess the "lower is better" paradigm. A patient-centered, risk-based approach to statin therapy is recommended. Large-scale randomized controlled trials are urgently needed to establish safe lipid thresholds and optimize therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.